Pomegra
Boston Scientific cut its 2026 sales growth forecast to 5.5–6.5% and launched a $700M–$800M restructuring program seeking $500M in annual savings by 2029.
- Full-year 2026 net sales growth guidance was lowered to 5.5%–6.5%, the second reduction since February's 10.5%–11.5% forecast.
- The global restructuring carries $700M–$800M in pre-tax charges, targeting $500M in annualized run-rate savings upon 2029 completion.
- Watchman left atrial appendage closure posted just 4.3% revenue growth in Q2 2026, with US growth of 3%, driving the bulk of the downward revision.
Lead
Boston Scientific (NYSE: BSX) on August 7, 2026, cut its full-year 2026 net sales growth forecast to 5.5%–6.5%, down from 7%–8.5% guidance issued in April, as weakening demand for its Watchman heart closure device and competitive erosion in electrophysiology weighed on the second-half outlook. Alongside the guidance reduction, the Marlborough, Massachusetts-based medical device maker announced a global restructuring program expected to generate approximately $500 million in annualized pre-tax savings upon completion in 2029.What Happened
Boston Scientific reported second-quarter 2026 revenue of $5.44 billion, a 7.5% year-over-year increase that surpassed consensus estimates of $5.38 billion. Adjusted earnings per share rose 15% to $0.86, exceeding the $0.83 analyst estimate. Despite those beats, management sharply trimmed the revenue and earnings outlook for the remainder of the year.
Full-year 2026 adjusted EPS guidance was narrowed to $3.28–$3.32, from $3.34–$3.41. The reset is striking in scale: Boston Scientific entered 2026 projecting organic revenue growth of 10.5%–11.5%, making the current 5.5%–6.5% range roughly half the original target.
Watchman and Electrophysiology Under Pressure
The sharpest headwind came from Watchman, the company's flagship left atrial appendage closure (LAAC) implant for atrial fibrillation patients. Watchman revenue of $507 million in Q2 reflected growth of just 4.3% overall, with US growth of 3% against 18% internationally. Management now guides to flat-to-low single-digit Watchman growth for the full year, citing a structural shift in clinical practice: physicians are increasingly combining Watchman implantation with other cardiac procedures rather than performing it as a standalone operation, compressing standalone procedure volumes.
Electrophysiology (EP) delivered an additional negative surprise, with US competitive pressures driving a revised second-half outlook of essentially flat growth. Planned product launches—including the FARAWAVE Ultra ablation catheter and expansion into the intracardiac echocardiography market—are positioned as recovery catalysts in 2027.
The pressure on Watchman and EP contrasts with relative stability across Boston Scientific's broader cardiac stent and interventional cardiology franchise, where the company maintained positioning despite a tighter hospital-budget environment. Still, the concentration of the shortfall in two of the company's fastest-growing segments exposed the limits of that diversification buffer.
Restructuring Program
To offset the revenue shortfall and reposition its cost structure, Boston Scientific announced a global restructuring running from 2026 through 2029. Total pre-tax charges are estimated at $700 million to $800 million, comprising approximately $300 million–$350 million in manufacturing transfer costs, $275 million–$300 million in employee termination benefits, and $125 million–$150 million in other reorganization expenses.
The initiative targets approximately $500 million in gross annual pre-tax run-rate savings upon full completion. Management indicated that more than half of the projected savings—and the associated program spending—will be realized by the end of 2027. A portion of the savings is designated for reinvestment in growth priorities including new device development and commercial infrastructure, consistent with Boston Scientific's history of pairing restructuring programs with targeted portfolio investment.
Market Reaction
Boston Scientific shares declined approximately 12% over the week following the earnings release, reflecting investor concern over the magnitude and speed of the Watchman deceleration. The selloff underperformed the broader medical device sector index as markets recalibrated the durability of the company's high-growth narrative, which had been built around structural heart and EP franchises commanding premium multiples.
Strategic Context
Boston Scientific has been among the fastest-growing large-cap medical device companies in recent years, propelled by Watchman's dominance in the LAAC market and a robust EP pipeline anchored by its pulsed-field ablation platform. The Q2 reset occurs as Abbott Laboratories (NYSE: ABT) sharpens its own LAAC and EP positioning—Abbott recently repositioned its Amplatzer franchise within its EP business, reflecting the deepening convergence of structural heart and electrophysiology that is intensifying competitive dynamics across the sector. Medtronic (NYSE: MDT) is pressing similar competitive claims in EP.
The simultaneous moderation in the cardiac stent and structural heart categories reflects broader hospital-utilization normalization following elevated post-pandemic procedure volumes, a dynamic weighing on peers across the sector.
Outlook
Boston Scientific enters the second half of 2026 with revised expectations for its two highest-growth franchises, a restructuring program that will generate near-term cost headwinds before delivering savings, and a pipeline of product launches intended to restore momentum in 2027. The restructuring's scale—approaching $800 million in total charges—signals management is treating this as a structural reset rather than a tactical adjustment. Whether FARAWAVE Ultra and international Watchman expansion can offset sustained US softness will be the central question for investors over the next three to four quarters.
